Antiviral Innate Responses Induced by VSV-EBOV Vaccination Contribute to Rapid Protection
Ebola virus (EBOV) is the causative agent of Ebola virus disease (EVD), a deadly disease and major public health threat worldwide. A safe and highly efficacious vesicular stomatitis virus-based vaccine against EBOV is the only platform that has successfully completed phase III clinical trials and ha...
Main Authors: | Andrea R. Menicucci, Allen Jankeel, Heinz Feldmann, Andrea Marzi, Ilhem Messaoudi |
---|---|
Format: | Article |
Language: | English |
Published: |
American Society for Microbiology
2019-05-01
|
Series: | mBio |
Subjects: | |
Online Access: | https://doi.org/10.1128/mBio.00597-19 |
Similar Items
-
To B or Not to B: Mechanisms of Protection Conferred by rVSV-EBOV-GP and the Roles of Innate and Adaptive Immunity
by: Amanda N. Pinski, et al.
Published: (2020-09-01) -
Protection Against Marburg Virus Using a Recombinant VSV-Vaccine Depends on T and B Cell Activation
by: Andrea Marzi, et al.
Published: (2019-01-01) -
Ebola Virus Glycoprotein Domains Associated with Protective Efficacy
by: Bharti Bhatia, et al.
Published: (2021-06-01) -
Safety of Recombinant VSV–Ebola Virus Vaccine Vector in Pigs
by: Emmie de Wit, et al.
Published: (2015-04-01) -
Vesicular Stomatitis Virus: From Agricultural Pathogen to Vaccine Vector
by: Guodong Liu, et al.
Published: (2021-08-01)